Better Marijuana Stock to Buy Right Now: Tilray or Trulieve?

Trulieve began trading on the NYSE under ticker TRUL on June 10 after U.S. rescheduling of medical marijuana to Schedule III enabled the uplisting. The article argues Trulieve is fundamentally stronger than Tilray, citing Q1 adjusted EBITDA of $100 million, Q1 revenue of $287 million, 59% gross margin, and positive EPS of $0.01 versus Tilray's $206.7 million revenue, 27% blended gross margin, and EPS loss of $0.24. The piece is a relative-value comparison within cannabis, with the biggest upside tied to lower 280E tax burdens after rescheduling.

Analysis

The market is likely to treat this as an earnings-quality rerating rather than a simple sentiment trade. The key second-order effect is that a major-exchange listing gives the U.S. operator a broader institutional ownership base right as its tax burden may structurally step down; that combination can compress the valuation gap versus weaker international peers faster than headline revenue growth would suggest. In other words, the move is less about one quarter of reported profits and more about the market assigning a higher terminal multiple to cash flow that is no longer being taxed like a quasi-illegal business.

Tilray’s problem is not just lower margins; it is that its margin structure is more exposed to commodity-like pricing and less able to self-correct. If Canadian wholesale pricing keeps drifting lower, any revenue gains from distribution breadth can be offset by operating leverage in the wrong direction, especially because cultivation and compliance costs do not reset as quickly as flower prices. That makes TLRY a cleaner short on relative fundamentals than a directional short on the sector, since the company’s beverage optionality is too small today to offset core cannabis compression.

The contrarian angle is that the headline catalyst may be better for the whole basket than the article implies. NYSE listing plus tax relief can invite generalist capital back into U.S. cannabis, which could lift the weakest balance-sheet names on multiple expansion even if operating performance lags. That means the cleanest expression is not outright short sector, but long the operator with the best path to durable free cash flow versus short the structurally lower-margin, more exposed wholesale model.

Timing matters: the first leg should happen over days to weeks as index/ETF and crossover funds establish exposure, but the more important leg is over 1-2 quarters as investors mark through the tax benefit and re-rate earnings power. The main reversal risk is policy disappointment: if federal rescheduling stalls in implementation, or if exchange-listed access becomes a ‘sell the news’ event with no follow-through in institutional flows, the multiple expansion could fade quickly. In that case, the winner is still the higher-quality balance sheet, but the trade works best as a relative-value spread rather than a naked long.

Key Decisions for Investors

• Go long TRUL / short TLRY as a 3-6 month relative-value pair trade; the setup favors the operator with cleaner cash-flow conversion and upcoming tax relief versus the lower-margin wholesaler exposed to price compression.
• Add to TLRY short exposure on any post-listing rally above the event-driven move, with a 4-8 week horizon; use a tight risk limit because sector-wide multiple expansion could lift all names temporarily.
• For more convex exposure, buy TRUL call spreads 2-4 months out, funded partially by selling out-of-the-money calls on TLRY or a weaker peer; this captures rerating while capping theta burn if the catalyst takes longer to matter.
• Avoid initiating fresh long exposure in low-quality Canadian wholesale names until there is evidence of pricing stabilization over 1-2 quarters; the fundamental inflection is slower than the headline catalyst suggests.
• If you want basket exposure, prefer a long TRUL / long CRON-neutral or underweight structure over a broad cannabis long; the market may reward quality dispersion more than sector beta.